CoChat

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Open access
Isozaki, Hideko, Sakhtemani, Ramin, Abbasi, Ammal, Nikpour, Naveed, Stanzione, Marcello, Oh, Sunwoo, Langenbucher, Adam, Monroe, Susanna, Su, Wenjia, Cabanos, Heidie Frisco, Siddiqui, Faria M., Phan, Nicole, Jalili, Pégah, Timonina, Daria, Bilton, Samantha, Gomez-Caraballo, Maria, Archibald, Hannah L., Nangia, Varuna, Dionne, Kristin, Riley, Amanda, Lawlor, Matthew, Banwait, Mandeep Kaur, Cobb, Rosemary G., Zou, Lee, Dyson, Nicholas J., Ott, Christopher J., Benes, Cyril, Getz, Gad, Chan, Chang S., Shaw, Alice T., Gainor, Justin F., Lin, Jessica J., Sequist, Lecia V., Piotrowska, Zofia, Yeap, Beow Y., Engelman, Jeffrey A., Lee, Jake June-Koo, Maruvka, Yosef E., Buisson, Rémi, Lawrence, Michael S., Hata, Aaron N. · 2023 · Nature
Cited by 158

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Induction of APOBEC3A in response to targeted therapies drives evolution of drug-tolerant persister cells, suggesting that its suppression may represent a potential therapeutic strategy in the prevention of acquired resistance to lung cancer targeted therapy. Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified^ 1 – 4 , the underlying molecular mechanisms shaping tumour evolution during treatment are incompletely understood. Genomic profiling of patient tumours has implicated apolipoprotein B messenger RNA editing catalytic polypeptide-like (APOBEC) cytidine deaminases in tumour evolution; however, their role during therapy and the development of acquired drug resistance is undefined. Here we report that lung cancer targeted therapies commonly used in the clinic can induce cytidine deaminase APOBEC3A (A3A), leading to sustained mutagenesis in drug-tolerant cancer cells persisting during therapy. Therapy-induced A3A promotes the formation of double-strand DNA breaks, increasing genomic instability in drug-tolerant persisters. Deletion of A3A reduces APOBEC mutations and structural variations in persister cells and delays the development of drug resistance. APOBEC mutational signatures are enriched in tumours from patients with lung cancer who progressed after extended responses to targeted therapies. This study shows that induction of A3A in response to targeted therapies drives evolution of drug-tolerant persister cells, suggesting that suppression of A3A expression or activity may represent a potential therapeutic strategy in the prevention or delay of acquired resistance to lung cancer targeted therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06303-1

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 158

Metadata

Authors
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., Siddiqui, F. M., Phan, N., Jalili, P., Timonina, D., Bilton, S., Gomez-Caraballo, M., Archibald, H. L., Nangia, V., Dionne, K., Riley, A., Lawlor, M., Banwait, M. K., Cobb, R. G., Zou, L., Dyson, N. J., Ott, C. J., Benes, C., Getz, G., Chan, C. S., Shaw, A. T., Gainor, J. F., Lin, J. J., Sequist, L. V., Piotrowska, Z., Yeap, B. Y., Engelman, J. A., Lee, J. J.-K., Maruvka, Y. E., Buisson, R., Lawrence, M. S., & Hata, A. N.
Venue
Nature
Published
2023-07-05
Volume
620
Issue
7973
Pages
393-401
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4383265707
Cited by
158
References
30
FWCI
14.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapy-induced APOBEC3A drives evolution of persistent cancer cells. https://app.cochat.ai/papers/10.1038/s41586-023-06303-1
The paper
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., Siddiqui, F. M., Phan, N., Jalili, P., Timonina, D., Bilton, S., Gomez-Caraballo, M., Archibald, H. L., Nangia, V., Dionne, K., . . . Hata, A. N. (2023). Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. https://doi.org/10.1038/s41586-023-06303-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.